Robert W. Baird restated their outperform rating on shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) in a research report sent to investors on Tuesday. The firm currently has a $40.00 price target on the specialty pharmaceutical company’s stock.
PRTK has been the subject of a number of other reports. BTIG Research started coverage on shares of Paratek Pharmaceuticals in a report on Thursday, December 22nd. They issued a buy rating and a $47.00 target price for the company. Zacks Investment Research cut shares of Paratek Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, February 15th. Cantor Fitzgerald set a $28.00 target price on shares of Paratek Pharmaceuticals and gave the company a buy rating in a report on Tuesday, December 13th. Guggenheim reaffirmed a buy rating on shares of Paratek Pharmaceuticals in a report on Monday, March 27th. Finally, Wedbush reaffirmed an outperform rating and issued a $30.00 target price on shares of Paratek Pharmaceuticals in a report on Monday, April 3rd. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $36.78.
Paratek Pharmaceuticals (NASDAQ:PRTK) traded up 1.736% during mid-day trading on Tuesday, reaching $21.975. The company’s stock had a trading volume of 816,312 shares. The firm’s market capitalization is $533.68 million. Paratek Pharmaceuticals has a 52 week low of $9.80 and a 52 week high of $25.00. The company’s 50-day moving average price is $18.64 and its 200 day moving average price is $15.06.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its earnings results on Thursday, March 2nd. The specialty pharmaceutical company reported ($1.16) EPS for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.17. The business earned $0.03 million during the quarter.
In other Paratek Pharmaceuticals news, CFO Douglas W. Pagan sold 3,405 shares of the company’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $15.09, for a total transaction of $51,381.45. Following the transaction, the chief financial officer now directly owns 58,983 shares in the company, valued at $890,053.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Evan Loh sold 3,106 shares of the company’s stock in a transaction dated Monday, February 6th. The stock was sold at an average price of $15.09, for a total transaction of $46,869.54. Following the transaction, the chief operating officer now owns 102,873 shares in the company, valued at $1,552,353.57. The disclosure for this sale can be found here. Insiders have sold 11,511 shares of company stock worth $173,701 over the last 90 days. 2.00% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN raised its position in shares of Paratek Pharmaceuticals by 196.5% in the third quarter. Wells Fargo & Company MN now owns 8,005 shares of the specialty pharmaceutical company’s stock valued at $104,000 after buying an additional 5,305 shares during the last quarter. Ardsley Advisory Partners acquired a new stake in Paratek Pharmaceuticals during the third quarter valued at approximately $130,000. Dynamic Technology Lab Private Ltd acquired a new stake in Paratek Pharmaceuticals during the fourth quarter valued at approximately $158,000. Ellington Management Group LLC acquired a new stake in Paratek Pharmaceuticals during the fourth quarter valued at approximately $179,000. Finally, Baird Financial Group Inc. acquired a new stake in Paratek Pharmaceuticals during the fourth quarter valued at approximately $216,000. Institutional investors own 76.06% of the company’s stock.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc (Paratek), formerly Transcept Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).
Receive News & Ratings for Paratek Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.